Fifteen-minute consultation: The review of a child with trisomy 21 (Down’s syndrome)

Dalrymple, Rebecca Amy; Somerville, Laura Helen; Hamza, Sherin; Matta, Nashwa

doi:10.1136/archdischild-2020-319814

Cited by 8 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2022; Dalrymple et al . 2022). Furthermore, despite the recently development of guidelines aimed to the adult DS population (Tsou et al ., 2020), which had been previously focused to a greater extent on paediatric population, strong recommendations for the assessment and monitoring of serum lipid levels remain unclear given the scarcity of robust evidence needed to support them.…”

Section: Discussionmentioning

confidence: 99%

“…There is a lack of conclusive evidence regarding the influence of cardiovascular risk factors on the incidence of cardiovascular events in DS individuals. Current health guidelines for DS mainly emphasise BMI monitoring and obesity prevention through educational efforts; however, the recommendation for periodic monitoring of the lipid profile is not indicated (Lizama et al 2013;Flores et al 2021;Michael & Marder 2021;Bull et al 2022;Dalrymple et al 2022). Furthermore, despite the recently development of guidelines aimed to the adult DS population (Tsou et al, 2020), which had been previously focused to a greater extent on paediatric population, strong recommendations for the assessment and monitoring of serum lipid levels remain unclear given the scarcity of robust evidence needed to support them.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and meta‐analysis of serum lipid concentrations in people with Down syndrome

Gastelum Guerrero,

Cháidez Fernández,

Magaña Ordorica

et al. 2024

J intellect Disabil Res

View full text Add to dashboard Cite

BackgroundDown syndrome (DS) is the most prevalent chromosomal disorder, being the leading cause of intellectual disability. The increased life expectancy of individuals with DS has led to a shift in the incidence of non‐communicable chronic diseases, resulting in new concerns, particularly cardiovascular disease (CVD) and Alzheimer's disease. This study aimed to analyse the blood lipid profile of a large DS cohort to establish a baseline for evaluating health risk parameters.MethodsA comprehensive literature search was conducted on PubMed and Virtual Health Library databases to identify original articles published before July 2022. Selected studies were included in the meta‐analysis.ResultsFifteen studies reporting serum lipid levels in individuals with DS were incorporated into the analysis. The meta‐analysis used the means and standard deviations extracted from the selected studies. The analysis encompassed 671 participants in the DS group and 898 euploid controls. The results indicated significant differences in total cholesterol [C] (mean difference [MD]: −3.34; CI: 95%: −4.94 to −1.73; P < 0.0001), HDL‐C (MD: −3.39; CI: 95%: −6.72 to −0.06; P = 0.05) and triglycerides (MD: 21.48; CI: 95%: 9.32 to 33.65; P = 0.0005) levels between individuals with DS and their control counterparts.ConclusionsIndividuals with DS have less favourable blood lipid concentrations than their controls, particularly HDL‐C, triglycerides, and total‐C, even when grouped by age. These findings underscore the importance of closer monitoring of lipid profiles in people with DS and the necessity for specific cut‐offs for this population, considering the risk for ischemic heart and Alzheimer's diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A systematic review and meta‐analysis of serum lipid concentrations in people with Down syndrome

Gastelum Guerrero,

Cháidez Fernández,

Magaña Ordorica

et al. 2024

J intellect Disabil Res

View full text Add to dashboard Cite

show abstract

“…Seizures occur in about 5-13% that may present as infantile spasms or generalized tonic-clonic or myoclonic seizures. Common developmental problems include autism spectrum disorder in 16% and attention deficit hyperactivity disorder (ADHD) in six percent of cases [ 6 , 7 ]. Neutrophilia, thrombocytopenia, and polycythemia, collectively known as hematological abnormalities in newborns with DS (HANDS), is a well-recognized complication in the newborn period [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

Cleft Palate in a Newborn With Trisomy 21: A Case Report

Cabanas,

Falconi,

Jones

et al. 2023

Cureus

View full text Add to dashboard Cite

Trisomy 21, or Down syndrome (DS), is neonates' most common chromosomal abnormality. In addition, children born with DS have an increased risk of congenital anomalies such as congenital heart defects, gastrointestinal abnormalities, and, rarely, cleft palate. Cleft lip and palate are among the most common congenital anomalies associated with many congenital syndromes; however, Trisomy 21 is the least common congenital anomaly associated with orofacial clefts. We present a case of cleft palate, duodenal stenosis, persistent pulmonary hypertension of the newborn, patent ductus arteriosus, and atrial septal defect in a newborn with classical clinical features of Down syndrome. This report discusses the uncommon presentation of trisomy 21 and concomitant cleft palate in a neonate, including its recognition and treatment, as no standard of care treatment exists.

show abstract

“…Meltem Küçükdağ 1, *, H Nejat Küçükdağ 2 Mathews Journal of Case Reports https://doi.org/10.30654/MJCR.10082…”

Section: Methylphenidate-induced Kleptomania In a Child With Down Syn...mentioning

confidence: 99%

“…Down syndrome (DS) is a commonly occurring chromosomal disorder that is associated with psychiatric comorbidity in 28.9% of cases [1]. The most common issues include general anxiety, obsessive-compulsive behaviours, neurodevelopmental disorders, depression, and sleep-related disorders [2]. Symptoms of ADHD are also prevalent in children with DS.…”

Section: Introductionmentioning

confidence: 99%

Methylphenidate-Induced Kleptomania in a Child with Down Syndrome

Küçükdağ¹,

Küçükdağ²

2023

MJCR

View full text Add to dashboard Cite

Methylphenidate is the most preferred drug in the treatment of ADHD, which is one of the psychiatric diseases that often accompany Down's syndrome. Methylphenidate, which is used safely in children and adolescents, may rarely show unexpected side effects. In our study, we present a case of kleptomania induced by methylphenidate in a child with Down syndrome, which resolved with the discontinuation of the drug.

show abstract

Fifteen-minute consultation: The review of a child with trisomy 21 (Down’s syndrome)

Cited by 8 publications

References 14 publications

A systematic review and meta‐analysis of serum lipid concentrations in people with Down syndrome

A systematic review and meta‐analysis of serum lipid concentrations in people with Down syndrome

Cleft Palate in a Newborn With Trisomy 21: A Case Report

Methylphenidate-Induced Kleptomania in a Child with Down Syndrome

Contact Info

Product

Resources

About